0
0
New Delhi, July 18, 2025:
A recent study by the Indian Council of Medical Research (ICMR) has found that administering higher doses of rifampicin, a cornerstone antibiotic in the treatment of pulmonary tuberculosis (TB), is safe and may offer improved recurrence-free survival for patients. The findings bring fresh hope in the ongoing fight against one of the world’s deadliest infectious diseases, which caused approximately 1.3 million deaths globally in 2022.
Key Findings from the Study
-
Current Dosage vs. Higher Dosage:
Standard treatment prescribes rifampicin at 10 mg per kg of body weight over six months for patients with lung TB. The ICMR review evaluated whether increasing the dosage to more than 15 mg/kg would yield better outcomes without jeopardizing patient safety. -
Faster Bacterial Clearance:
Patients who received higher doses, especially between 20 and 30 mg/kg, experienced faster conversion of their sputum tests from positive to negative within eight weeks—a key indicator of bacterial clearance and early treatment response. This rapid sputum conversion can lower the risk of disease transmission to others and is linked to a lower risk of relapse. -
Safety and Side Effects:
The study found that higher doses in the 20–30 mg/kg range offered the best balance between effectiveness and safety. These doses did not significantly increase the risk of serious adverse effects compared to the standard regimen. However, doses above 30 mg/kg were associated with an increase in severe side effects, including liver toxicity, which sometimes necessitated discontinuation of treatment. -
Impact on Mortality and Treatment Failure:
Despite the accelerated bacterial clearance, higher doses of rifampicin did not reduce mortality rates or the proportion of patients experiencing treatment failure at the six-month mark compared to standard treatment.
Implications for TB Treatment
According to Dr. Leeberk Raja Inbaraj of the ICMR-National Institute for Research in Tuberculosis, the accelerated sputum conversion with higher rifampicin doses could improve patient outcomes and reduce recurrence. Still, the study emphasized the importance of careful monitoring for potential adverse reactions, particularly liver damage, when using higher doses.
The researchers note that while the results are promising, larger and longer-term clinical trials are needed to fully understand the benefits and risks of high-dose rifampicin therapy in diverse populations.
Expert Commentary
-
Higher doses could drive recurrence-free cure and reduce transmission.
-
Doses above 30 mg/kg may increase the risk of severe side effects.
-
No significant benefit observed in mortality or treatment failure rates versus standard dosing.
Conclusion
The ICMR study adds to a growing body of evidence suggesting that optimizing rifampicin dosage could enhance TB treatment regimens. Public health officials urge clinicians to consider the risk-benefit balance carefully and call for more extensive studies to determine long-term outcomes.
Disclaimer
This article summarizes key findings from the latest research by the Indian Council of Medical Research on rifampicin dosing in lung TB. The information is intended for educational and informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Patients are advised to consult their healthcare providers before making any changes to their treatment regimen.
